Nuformix PLC Notice of Allowance of Patent in US (9518A)
07 June 2021 - 4:00PM
UK Regulatory
TIDMNFX
RNS Number : 9518A
Nuformix PLC
07 June 2021
Nuformix plc
("Nuformix" or the "Company")
Notice of Allowance of Patent in US
Nuformix plc (LSE: NFX), a pharmaceutical development company
targeting unmet medical needs in fibrosis and oncology via drug
repurposing, is pleased to announce that it has received a Notice
of Allowance for a U.S. National Phase Patent Application No.
17/051,592 entitled "CRYSTALLINE TRANILAST SALTS AND THEIR
PHARMACEUTICAL USE".
NXP002 is the Company's pre-clinical lead asset and a potential
novel inhaled treatment for Idiopathic Pulmonary Fibrosis ("IPF").
It is a repurposed, new form of the drug tranilast, to be delivered
in an inhaled formulation. Nuformix filed two patent applications
on new crystalline forms of tranilast, one of which has been
granted globally and this second patent application has now been
allowed in the US and has also been approved for the "Patent
Prosecution Highway" which may accelerate examination in other
countries.
As previously communicated, since completing the successful
fundraise in March 2021, Nuformix has started additional
pre-clinical studies on NXP002 through outsourced expert contract
organisations to generate a more robust data package with the goal
of increasing the value of the NXP002 asset to render it more
attractive to licensing partners.
Dr Anne Brindley, CEO of Nuformix, said: "I am very pleased that
we have received this Notice of Allowance from the US Patent Office
meaning that this patent will proceed to be issued. This is an
important endorsement of Nuformix's discoveries and also
strengthens the patent estate for our lead asset NXP002. The US is
the largest market for IPF (over 60% of the global market) and thus
this is a key step forward for the Company and this asset."
Enquiries:
Nuformix plc +44 (0)1223 627 222
Dr Anne Brindley, CEO
Allenby Capital Limited +44 (0)20 3328 5656
Nick Athanas / George Payne (Corporate
Finance)
Tim Sohal / Matt Butlin (Sales
& Corporate Broking)
Walbrook PR +44 (0)20 7933 8780 or nuformix@walbrookpr.com
Anna Dunphy / Paul McManus / Kiki
Zaccagnini
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet
medical needs in fibrosis and oncology via drug repurposing. The
Company aims to use its expertise in discovering, developing and
patenting novel drug forms, with improved physical properties, to
develop new products in new indications that are, importantly,
differentiated from the original (by way of dosage, delivery route
or presentation), thus creating new and attractive commercial
opportunities. Nuformix has an early-stage pipeline of preclinical
and Phase 1-ready assets with potential for significant value and
early licensing opportunities.
For more information, please visit www.nuformix.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCKZGGVZVKGMZM
(END) Dow Jones Newswires
June 07, 2021 02:00 ET (06:00 GMT)
Nuformix (LSE:NFX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Nuformix (LSE:NFX)
Historical Stock Chart
From Jul 2023 to Jul 2024